Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.59 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326817 | 1.00 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326815 | 1.00 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL31327361 | 0.98 | SLC6A3 (0.58) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL670331 | 0.94 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL2844473 | 0.94 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL2842321 | 0.94 | SLC6A3 (0.53) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Alcohol SCHEMBL28321747 | 0.90 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326911 | 0.90 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10327324 | 0.90 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326624 | 0.90 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| CN-118993986-A | Optimized preparation method of 2-benzhydryl piperidine hydrochloride | 上海原思标物科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240038401-A1 | METHOD FOR PREDICTING RESPONSE OF A SUBJECT TO ANTIDEPRESSANT TREATMENT | TALIAZ LTD. (IL) | 2024-02-01 | — | — | US | claimed |
| EP-4205136-A1 | METHOD FOR PREDICTING RESPONSE OF A SUBJECT TO ANTIDEPRESSANT TREATMENT | Taliaz Ltd. (IL) | 2023-07-05 | — | — | EP | claimed |
| US-20220323380-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | ISANAS AG (CH) | 2022-10-13 | — | — | US | claimed |
| US-20220145354-A1 | METHOD AND SYSTEM FOR PREDICTING RESPONSE OF A SUBJECT TO ANTIDEPRESSANT TREATMENT | TALIAZ LTD. (IL) | 2022-05-12 | — | — | US | claimed |
| EP-3986391-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Isanas AG (CH) | 2022-04-27 | — | — | EP | claimed |
| WO-2018078631-A1 | METHOD AND SYSTEM FOR PREDICTING RESPONSE OF A SUBJECT TO ANTIDEPRESSANT TREATMENT | TALIAZ LTD. (IL) | 2018-05-03 | — | — | WO | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| WO-2000024715-A1 | PIPERIDINE COMPOUNDS AND THEIR USE IN THE POPULATION CONTROL OF RODENTS AND OTHER VERTEBRATE PESTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-05-04 | — | — | WO | claimed |